Comparison of two different types of hormone therapy effects on haemostatic parameters in early postmenopausal women

Tasić, Lidija; Dunjic, Radica; Vasiljevic, Mladenko; Dikić, Svetlana Dragojević; Jurisic, A.; Tasic, Dijana

doi:10.2298/sarh1102052t

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of those, 51 were excluded after initial screening and the remaining 13 full text papers were reviewed. Finally, 12 were scrutinized as full texts and were selected to be included in the analysis (32,35,(41)(42)(43)(44)(45)(46)(47)(48)(49)(50). One article was excluded because of incomplete data (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials

Bała

Sahebkar

Ursoniu

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

Tibolone is a synthetic steroid with estrogenic, androgenic and progestogenic activity, but the evidence regarding its effects on fibrinogen and antithrombin III (ATIII) has not been conclusive. We assessed the impact of tibolone on fibrinogen and ATIII through a systematic review and meta-analysis of available randomized controlled trials (RCTs). The search included PUBMED, Web of Science, Scopus, and Google Scholar (up to January 31st, 2016) to identify controlled clinical studies investigating the effects of oral tibolone treatment on fibrinogen and ATIII. Overall, the impact of tibolone on plasma fibrinogen concentrations was reported in 10 trials comprising 11 treatment arms. Meta-analysis did not suggest a significant reduction of fibrinogen levels following treatment with tibolone (WMD: -5.38%, 95% CI: -11.92, +1.16, p=0.107). This result was robust in the sensitivity analysis and not influenced after omitting each of the included studies from meta-analysis. When the studies were categorized according to the duration of treatment, there was no effect in the subsets of trials lasting either <12months (WMD: -7.64%, 95% CI: -16.58, +1.29, p=0.094) or ≥12months (WMD: -0.62%, 95% CI: -8.40, +7.17, p=0.876). With regard to ATIII, there was no change following treatment with tibolone (WMD: +0.74%, 95% CI: -1.44, +2.93, p=0.505) and this effect was robust in sensitivity analysis. There was no differential effect of tibolone on plasma ATIII concentrations in trials with either <12months (WMD: +2.26%, 95% CI: -3.14, +7.66, p=0.411) or≥12months (WMD: +0.06%, 95% CI: -1.16, +1.28, p=0.926) duration. Consistent with the results of subgroup analysis, meta-regression did not suggest any significant association between the changes in plasma concentrations of fibrinogen (slope: +0.40; 95% CI: -0.39, +1.19; p=0.317) and ATIII (slope: -0.17; 95% CI: -0.54, +0.20; p=0.374) with duration of treatment. In conclusion, meta-analysis did not suggest a significant reduction of fibrinogen and ATIII levels following treatment with tibolone.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials

Bała

Sahebkar

Ursoniu

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…When estimating the risk for thromboembolic complication associated with MHT, it is necessary to take into account the presence of the individual risk factors for every patient [46]. TREATS study (The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening) has shown that genetic affinity to thrombophilia has also an important role in the occurrence of increased risk for venous thromboembolism (VTE) in MHT users who are carriers of factor V Leiden mutation [47].…”

Section: Introduction Monitoring and Discontinuation Of Mhtmentioning

confidence: 99%